The aim of the Consorcio Centro de Investigación Biomédica en Red, M.P, CIBER, a public research consortium set up at the initiative of the Instituto de Salud Carlos III (ISCIII) is to further excellence research in Biomedicine and Health Sciences done in the National Health System and in the Science and Technology System. To this end efforts and interdisciplinary and multi-institutional research are combined with a preferential dedication of financial resources around knowledge networks formed by centres and research groups reporting to different administrations and public and private institutions.
Cardiac Damage and Associated Consequences
The research in this program is organized into three main lines:
1) Myocardial Healing and Remodelling. The objective of this line is to clarify the molecular, structural, and functional mechanisms of cardiac tissue healing and the processes of atrial and ventricular remodelling. The new knowledge generated can be applied to develop, evaluate and validate advanced innovative therapies both in the pre-clinical setting and in the clinical setting.
2) Genetic Myocardial Damage. The objective of this line is to increase our knowledge of genetic cardiomyopathies and channelopathies in order to improve the effectiveness of current and novel treatments.
3) Heart Failure. The objective of this line is to prevent and effectively treat heart failure in order to improve patient quality of life and to reduce the incidence of the disease and the associated costs to the health system.
Molecular and Imaging Biomarkers; Precision Cardiovascular Medicine
The research in this program is organized in two main lines:
1) Evaluation of Known Biomarkers with the goal to assess the performance of isolated or combined biomarkers already described as tools for phenotyping CV patients, or staging the extent and prognosis of CV conditions, or personalizing and monitoring the response to therapeutic CV interventions.
2) Identification of Novel Biomarkers with the goal to characterize candidate circulating and imaging biomarkers indicators of normal CV biological processes or CV pathological processes, and that can be potentially used for the clinical handling of CV patients because enable repeated and accurate measurements with a rapid turnaround time at reasonable cost.